Monopar Therapeutics
Filed with the SEC on · accession 0001437749-26-036384
MNPR filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved +1.3% by the first close after the filing.
Monopar Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting routine financial results and disclosures including equity compensation activity and cash equivalents.
Close before
$71.73
Nov 11, 2026
First close after
+1.32%
$72.68
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for MNPR, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for MNPR?
Click hereMNPR filed a 10-Q (SEC filing). Monopar Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting routine financial results and disclosures including equity compensation activity and cash equivalents.
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
MNPR closed at $71.73 before the filing and $72.68 on Nov 12, 2026 (+1.32%).
Get alerts when MNPR files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days